Grundy McKenzie K, Buckanovich Ronald J, Bernstein Kara A
Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Division of Hematology Oncology, Department of Internal Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
NAR Cancer. 2020 Sep;2(3):zcaa024. doi: 10.1093/narcan/zcaa024. Epub 2020 Sep 25.
Regulation of homologous recombination (HR) is central for cancer prevention. However, too little HR can increase cancer incidence, whereas too much HR can drive cancer resistance to therapy. Importantly, therapeutics targeting HR deficiency have demonstrated a profound efficacy in the clinic improving patient outcomes, particularly for breast and ovarian cancer. RAD51 is central to DNA damage repair in the HR pathway. As such, understanding the function and regulation of RAD51 is essential for cancer biology. This review will focus on the role of RAD51 in cancer and beyond and how modulation of its function can be exploited as a cancer therapeutic.
同源重组（HR）的调控对于癌症预防至关重要。然而，HR过少会增加癌症发病率，而HR过多则会导致癌症产生治疗抗性。重要的是，针对HR缺陷的疗法已在临床上显示出显著疗效，改善了患者预后，尤其是对乳腺癌和卵巢癌。RAD51在HR途径的DNA损伤修复中起核心作用。因此，了解RAD51的功能和调控对于癌症生物学至关重要。本综述将聚焦于RAD51在癌症及其他方面的作用，以及如何利用其功能调控作为癌症治疗手段。
